ProKidney finishes enrollment for accelerated approval analysis in Phase 3 kidney disease trial
The company says it is now positioned for topline eGFR slope results in Q2 2027, with cash reported at $181.6 million as of June 30, 2026.
SEC filing
Latest
1 story